Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACETNASDAQ:AGLENASDAQ:ALPNNASDAQ:EOLSNASDAQ:FIXX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACETAdicet Bio$1.81-3.2%$2.28$1.10▼$7.50$154.07M1.88638,315 shs850,770 shsAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsALPNAlpine Immune Sciences$64.62+0.1%$42.90$6.71▼$64.70$4.23B1.144.23 million shs1.77 million shsEOLSEvolus$11.46-0.3%$13.48$7.07▼$15.43$666.35M1.45420,331 shs287,750 shsFIXXHomology Medicines$0.52$0.46▼$1.48$54.33M-0.1390,307 shs401,400 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACETAdicet Bio-3.47%-10.62%-19.20%-28.46%-69.32%AGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%+199.13%ALPNAlpine Immune Sciences+0.08%+0.29%+72.55%+157.25%+796.26%EOLSEvolus-0.35%-0.87%-17.26%-4.02%+36.27%FIXXHomology Medicines0.00%0.00%0.00%+168.59%+95.28%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACETAdicet Bio2.0667 of 5 stars3.31.00.00.02.33.30.6AGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AALPNAlpine Immune Sciences1.5814 of 5 stars2.14.00.00.02.83.30.0EOLSEvolus3.9866 of 5 stars3.52.00.03.52.52.50.6FIXXHomology Medicines2.3054 of 5 stars3.30.00.04.80.00.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACETAdicet Bio2.63Moderate Buy$12.83609.02% UpsideAGLEAeglea BioTherapeutics2.50Moderate Buy$17.50∞ UpsideALPNAlpine Immune Sciences2.27Hold$50.33-22.11% DownsideEOLSEvolus3.00Buy$20.6079.76% UpsideFIXXHomology Medicines2.50Moderate Buy$0.75∞ UpsideCurrent Analyst RatingsLatest EOLS, AGLE, ALPN, ACET, and FIXX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024ACETAdicet BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.004/16/2024ALPNAlpine Immune SciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/12/2024ALPNAlpine Immune SciencesSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$42.00 ➝ $65.004/11/2024ALPNAlpine Immune SciencesLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform4/11/2024ALPNAlpine Immune SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/11/2024ALPNAlpine Immune SciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral4/11/2024ALPNAlpine Immune SciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $65.004/11/2024ALPNAlpine Immune SciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Sector Perform$41.00 ➝ $65.004/11/2024ALPNAlpine Immune SciencesWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Peer Perform4/10/2024EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.004/9/2024ALPNAlpine Immune SciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACETAdicet Bio$24.99M5.95N/AN/A$2.43 per share0.74AGLEAeglea BioTherapeutics$2.33M0.00N/AN/A($60.61) per share0.00ALPNAlpine Immune Sciences$58.88M71.94N/AN/A$5.64 per share11.46EOLSEvolus$202.09M3.29N/AN/A($0.36) per share-31.83FIXXHomology Medicines$1.16M0.00N/AN/A$1.26 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACETAdicet Bio-$142.66M-$3.32N/AN/AN/AN/A-56.63%-48.16%5/14/2024 (Estimated)AGLEAeglea BioTherapeutics-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/AALPNAlpine Immune Sciences-$32.18M-$0.64N/AN/AN/A-54.66%-15.54%-11.34%5/9/2024 (Estimated)EOLSEvolus-$61.69M-$1.09N/AN/AN/A-30.52%N/A-32.19%5/7/2024 (Confirmed)FIXXHomology Medicines-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%5/9/2024 (Estimated)Latest EOLS, AGLE, ALPN, ACET, and FIXX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/AEOLSEvolus-$0.0650N/A+$0.0650N/AN/AN/A 3/19/2024Q4 2023ACETAdicet Bio-$0.72-$0.69+$0.03-$0.69$5.00 millionN/A3/18/2024Q4 2023ALPNAlpine Immune Sciences-$0.32$0.15+$0.47$0.15$6.90 million$30.85 million3/7/2024Q4 2023EOLSEvolus-$0.15-$0.20-$0.05-$0.19$61.14 million$61.00 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACETAdicet BioN/AN/AN/AN/AN/AAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AALPNAlpine Immune SciencesN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AFIXXHomology MedicinesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACETAdicet BioN/A8.418.41AGLEAeglea BioTherapeuticsN/A4.594.59ALPNAlpine Immune SciencesN/A7.867.86EOLSEvolusN/A2.332.10FIXXHomology MedicinesN/A7.257.25OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACETAdicet Bio83.89%AGLEAeglea BioTherapeuticsN/AALPNAlpine Immune Sciences75.17%EOLSEvolus90.69%FIXXHomology Medicines31.32%Insider OwnershipCompanyInsider OwnershipACETAdicet Bio29.50%AGLEAeglea BioTherapeutics6.60%ALPNAlpine Immune Sciences42.30%EOLSEvolus5.40%FIXXHomology Medicines16.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACETAdicet Bio14382.17 million57.93 millionOptionableAGLEAeglea BioTherapeutics694.05 million3.78 millionOptionableALPNAlpine Immune Sciences14265.55 million37.82 millionOptionableEOLSEvolus27357.94 million54.82 millionOptionableFIXXHomology Medicines758.13 million48.77 millionOptionableEOLS, AGLE, ALPN, ACET, and FIXX HeadlinesSourceHeadlineHomology Medicines, Inc.: Homology Medicines Declares Distribution to Common Stockholdersfinanznachrichten.de - March 24 at 4:56 AMFIXX Homology Medicines, Inc.seekingalpha.com - March 23 at 9:14 AMHomology Medicines Declares Distribution to Common Stockholdersfinance.yahoo.com - March 18 at 7:34 PMHomology Medicines files patent for recombinant aav capsid proteins for gene therapypharmaceutical-technology.com - March 11 at 10:14 AMHOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXbusinesswire.com - February 27 at 3:29 PMDepartment of Medicineuab.edu - February 14 at 8:20 AMHomology Medicines Inc (FIXX)investing.com - February 2 at 1:48 PMProniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawalpharmiweb.com - February 1 at 4:10 PMMedications & Treatmenthealthline.com - January 7 at 6:55 PMHomology Medicines, Inc.: Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiencyfinanznachrichten.de - January 4 at 8:30 AMHomology Medicines gets non-compliance notice from Nasdaqmsn.com - January 4 at 3:29 AMDepartment of Pathologyuab.edu - January 3 at 10:05 PMHomology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiencyfinance.yahoo.com - January 3 at 5:05 PMHomology Medicines Stock (NASDAQ:FIXX) Insider Tradesbenzinga.com - December 27 at 11:25 PMHomology Medicines Stock (NASDAQ:FIXX), Short Interest Reportbenzinga.com - December 27 at 11:25 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MIRO, SRC, PATI, FIXXmarkets.businessinsider.com - November 21 at 7:52 AMQ32 Bio raises new money and goes public via reverse mergerthepharmaletter.com - November 20 at 12:10 PMHOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXbusinesswire.com - November 17 at 10:18 PMHOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXXbusinesswire.com - November 17 at 8:02 PMBig Pharma-backed startup to go public by merging with gutted Homologybizjournals.com - November 17 at 12:17 PMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Homology Medicines (FIXX), Align Tech (ALGN) and Calidi Biotherapeutics (CLDI)markets.businessinsider.com - November 16 at 8:42 PMHomology enters reverse merger with Q32 Biobiopharmadive.com - November 16 at 8:42 PMHomology Medicines slumps after merger deal with Q32 Biomsn.com - November 16 at 3:41 PMWhy Is Rare Disease Focused Homology Medicines Stock Trading Lower Today?msn.com - November 16 at 3:41 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Global benchmarks mostly climb despite worries about US economyApril 26, 2024 3:21 AMView Stock market today: Global benchmarks mostly climb despite worries about US economyFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent3 Value Stocks Buffett Wishes He Could BuyApril 22, 2024 8:35 AMView 3 Value Stocks Buffett Wishes He Could BuyGold Rush: Exploring 5 Sector Giants Amidst Soaring PricesApril 4, 2024 6:10 AMView Gold Rush: Exploring 5 Sector Giants Amidst Soaring PricesAll Headlines Company DescriptionsAdicet BioNASDAQ:ACETAdicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.Aeglea BioTherapeuticsNASDAQ:AGLEAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Alpine Immune SciencesNASDAQ:ALPNAlpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.EvolusNASDAQ:EOLSEvolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Homology MedicinesNASDAQ:FIXXHomology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.